Eli Lilly (LLY) Gains as CVS Restores Zepbound, Adds Oral Foundayo to Formulary

Eli Lilly shares rose 3.4% on May 29, 2026, after CVS Health restored Zepbound as a co-preferred weight-loss option and added the company’s new oral pill Foundayo to its standard formulary. The move gives Lilly’s entire obesity portfolio simultaneous access to all three of the largest U.S. pharmacy benefit managers for the first time. CVS Caremark’s template covers 25 million to 30 million Americans, and employers adopting it will see Zepbound and Foundayo as equally accessible. Foundayo, an oral GLP-1 tablet, addresses needle aversion, a key barrier to adoption. Its formulary listing removes a typical slow launch ramp. Shares reached $1,124, a new 52-week high, and closed 3.6% higher than the prior session.